NCT06197126Not yet recruiting
MRI-based Signatures for Survival Prediction in Cervical Cancer With Radiotherapy
A Prognostic Model Based on MRI for Cervical Cancer Patients Treated With Radiotherapy
Source: ClinicalTrials.gov · Last updated 9 Jan 2024 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
This study aims to validate the value of tumor involvement features based on MRI in cervical cancer, facilitate the development of a more appropriate model for risk stratification, and help patients with varying risk profiles make appropriate decisions in treatment selection and follow-up plans.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 25 Dec 2023
- Start date
- 1 Jan 2024
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- Fujian Cancer Hospital
- Diseases
- Cervical cancer
- NCT number
- NCT06197126
What you commit to
- Study type: Observational
- Planned participants: 200
- From 1 Jan 2024 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- (1) lack of pre-treatment MRI, (2) prior anti-tumor treatment, (3) pelvic surgery history, (4) incomplete therapy, (5) loss of follow-up
Who the study is looking for
- (1) pathologically confirmed CC, (2) initially treated in our center
Age in the registry: 20 years to 85 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Fujian Cancer Hospital Coordinator of this site? Confirm its status | Fuzhou | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.